Estrogen receptor alpha single nucleotide polymorphism as predictor of diabetes type 2 risk in hypogonadal men

References

• Weihua Z, Lathe R, Warner M, Gustafsson JA. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 2002;99:13589–94
   PubMed Web of Science ®Google Scholar
• Clapauch R, Mattos TM, Silva P, et al. Total estradiol, rather than testosterone levels, predicts osteoporosis in aging men. Arq Bras Endocrinol Metabol 2009;53:1020–5
   PubMedGoogle Scholar
• Hill JW, Elmquist JK, Elias CF. Hypothalamic pathways linking energy balance and reproduction. Am J Physiol Endocrinol Metab 2008;294:E827–32
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male 2002;5:98–102
   PubMedGoogle Scholar
• Harada N, Ogawa H, Shozu M, et al. Biochemical and molecular genetic analyses on placental aromatase (P-450AROM) deficiency. J Biol Chem 1992;267:4781–5
   PubMedGoogle Scholar
• Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006;295:1288–99
   PubMed Web of Science ®Google Scholar
• Garcia-Arencibia M, Molero S, Davila N, et al. 17beta-Estradiol transcriptionally represses human insulin receptor gene expression causing cellular insulin resistance. Leuk Res 2005;29:79–87
   PubMed Web of Science ®Google Scholar
• McTernan PG, Anwar A, Eggo MC, et al. Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. Int J Obes Relat Metab Disord 2000;24:875–81
   PubMedGoogle Scholar
• Nadal A, Ropero AB, Laribi O, et al. Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen receptor alpha and estrogen receptor beta. Proc Natl Acad Sci USA 2000;97:11603–8
   PubMed Web of Science ®Google Scholar
• Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899–906
   PubMed Web of Science ®Google Scholar
• Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056–61
   PubMed Web of Science ®Google Scholar
• Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev 2001;81:1535–65
   PubMed Web of Science ®Google Scholar
• Revankar CM, Cimino DF, Sklar LA, et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005;307:1625–30
   PubMed Web of Science ®Google Scholar
• Ribas V, Nguyen MT, Henstridge DC, et al. Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERalpha-deficient mice. Am J Physiol Endocrinol Metab 2010;298:E304–19
   PubMed Web of Science ®Google Scholar
• Maffei L, Murata Y, Rochira V, et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004;89:61–70
   PubMed Web of Science ®Google Scholar
• Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689–98
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Morishima A, Bell J, Grumbach MM. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998;339:599–603
   PubMed Web of Science ®Google Scholar
• Herrmann BL, Saller B, Janssen OE, et al. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab 2002;87:5476–84
   PubMed Web of Science ®Google Scholar
• Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997;337:91–5
   PubMed Web of Science ®Google Scholar
• Romerius P, Giwercman A, Moell C, et al. Estrogen receptor alpha single nucleotide polymorphism modifies the risk of azoospermia in childhood cancer survivors. Pharmacogenet Genomics 2011;21:263–9
   PubMedGoogle Scholar
• Sundarrajan C, Liao WX, Roy AC, Ng SC. Association between estrogen receptor-beta gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders. J Clin Endocrinol Metab 2001;86:135–9
   PubMed Web of Science ®Google Scholar
• Aschim EL, Giwercman A, Stahl O, et al. The RsaI polymorphism in the estrogen receptor-beta gene is associated with male infertility. J Clin Endocrinol Metab 2005;90:5343–8
   PubMed Web of Science ®Google Scholar
• Svartberg J, Agledahl I, Figenschau Y, et al. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008;20:378–87
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Vermeulen A. Declining gonadal function in elderly men. Baillieres Clin Endocrinol Metab 1997;11:289–309
   PubMed Web of Science ®Google Scholar
• Agledahl I, Brodin E, Svartberg J, Hansen JB. Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels. Thromb Haemost 2009;102:945–50
   PubMedGoogle Scholar
• Dahlman I, Vaxillaire M, Nilsson M, et al. Estrogen receptor alpha gene variants associate with type 2 diabetes and fasting plasma glucose. Pharmacogenet Genomics 2008;18:967–75
   PubMed Web of Science ®Google Scholar
• Meshkani R, Saberi H, Mohammadtaghvaei N, Tabatabaiefar MA. Estrogen receptor alpha gene polymorphisms are associated with type 2 diabetes and fasting glucose in male subjects. Mol Cell Biochem 2012;359:225–33
   PubMed Web of Science ®Google Scholar
• Hunt R, Sauna ZE, Ambudkar SV, et al. Silent (synonymous) SNPs: should we care about them? Methods Mol Biol 2009;578:23–39
   PubMedGoogle Scholar
• Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183–217
   PubMed Web of Science ®Google Scholar